Can Ursodeoxycholic Acid Cause Loose Stools in Infants?
Yes, ursodeoxycholic acid (UDCA) can cause diarrhea or loose stools in infants, though this is typically dose-dependent and generally mild. This is a recognized gastrointestinal side effect that occurs across all age groups, including pediatric patients.
Evidence from Drug Labeling and Clinical Studies
The FDA drug label for UDCA explicitly states that the drug is "usually well tolerated, although mild cases of nausea and dizziness have been reported in up to 25% of patients" 1. More specifically, diarrhea is identified as a common adverse effect in the comprehensive pharmacovigilance analysis of FAERS data, where "diarrhea or loose stools" was among the most frequently reported adverse events associated with UDCA 2.
A systematic review of UDCA adverse effects confirms that "ursodeoxycholic acid caused diarrhoea in a small proportion of patients" 3. This effect appears to be dose-dependent, with higher doses more likely to produce gastrointestinal symptoms 4.
Pediatric-Specific Considerations
The FDA label explicitly states that "the safety and effectiveness of Ursodiol in pediatric patients have not been established" 1. This is a critical caveat when prescribing UDCA to infants.
Despite limited formal approval, UDCA is used in pediatric cholestatic conditions. In pregnancy guidelines (which provide insight into fetal/neonatal safety), UDCA is classified as FDA Category B and is noted to have "low risk" with "no adverse effects in mothers or newborns observed" in studies using UDCA for up to 8 weeks 5. The guideline further states that "significant amounts of UDCA cannot be found in milk during lactation," suggesting minimal transfer to breastfed infants 5.
Clinical Context and Management
When loose stools occur in infants on UDCA:
- This is typically a benign, self-limiting side effect rather than a sign of serious toxicity
- The mechanism relates to UDCA's effects on bile acid composition and intestinal secretion
- Dose adjustment may be warranted if diarrhea is problematic, as the effect is dose-dependent 4
- Typical pediatric dosing ranges from 10-20 mg/kg/day, with caution advised above 20 mg/kg/day 6, 7
Important Caveats
Distinguish UDCA-induced loose stools from other causes:
- Underlying cholestatic liver disease itself can cause malabsorption and diarrhea
- Fat-soluble vitamin deficiencies (particularly vitamin D and K) from cholestasis can contribute to gastrointestinal symptoms
- In conditions like FIC1 disease, chronic diarrhea is part of the disease itself due to abnormal microvilli in intestinal cells, not necessarily from UDCA 7
The benefit-risk assessment matters: While loose stools can occur, UDCA remains the first-line treatment for many pediatric cholestatic conditions, including intrahepatic cholestasis of pregnancy effects on the fetus 8, and certain genetic cholestatic diseases 9. The gastrointestinal side effects are generally outweighed by the therapeutic benefits in appropriate indications.
Monitor but don't automatically discontinue: If loose stools develop, assess severity, hydration status, and consider dose reduction before stopping therapy entirely, particularly in conditions where UDCA provides clear benefit.